MarginsXMarginsX
Home › Data Desk › Kiora Pharmaceuticals Inc.'s 10-Q carries going-concern doubt

MarginsX Data Desk · Going-concern doubt · Licensing and milestone payments · Late-stage clinical trials · Warrants and inducements

Kiora Pharmaceuticals Inc.'s 10-Q carries going-concern doubt

Kiora Pharmaceuticals Inc. (KPRX) told investors in its 10-Q on Nov 12, 2026 that there is substantial doubt it can continue operating as a going concern. (SEC EDGAR, 10-Q, Nov 12, 2026)

By the MarginsX Data Desk, automated. Published November 14, 2026. Data as of November 12, 2026.

Line chart of Kiora Pharmaceuticals Inc. (KPRX) daily closes from Jul 6, 2026 to Nov 12, 2026, with the going-concern filing on Nov 12, 2026 marked.

The filing reads: “The factors described above have caused management to determine there is substantial doubt about the Company's ability to continue as a going concern.” (SEC EDGAR, 10-Q, Nov 12, 2026)

Why we call it new

Its previous periodic report, the 10-Q filed Aug 7, 2026, did not match EDGAR full-text search for going-concern language when we last ran it on Nov 14, 2026. (SEC EDGAR, 10-Q, Aug 7, 2026)

Cash and dilution

It reported cash of $5.6M as of Sep 30, 2026. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)

At its recent quarterly burn rate that cash lasts about 8.6 months, by our estimate from its XBRL cash flows. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)

Its share count rose 20.3% over the past year. (Company health, computed by us from SEC filings and XBRL, Nov 10, 2026)

The stock

The Nasdaq screener puts its market value at $5.4M. (Nasdaq stock screener, Nov 13, 2026)

Follow it up

The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/KPRX)

The filing on SEC EDGAR. (sec.gov)

The filing in the MarginsX reader. (MarginsX reader)

Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.

Facts behind this article

FactValueSourceAs of
NameKiora Pharmaceuticals Inc.Source2026-11-13
Form10-QSource2026-11-12
WhoKiora Pharmaceuticals Inc. (KPRX)Source2026-11-13
SymbolKPRXSource2026-11-13
FiledNov 12, 2026Source2026-11-12
SentenceThe factors described above have caused management to determSource2026-11-12
Prev form10-QSource2026-08-07
Prev filedAug 7, 2026Source2026-08-07
Fts checkedNov 14, 2026Source2026-11-14
Cash5,570,640 USDSource2026-09-30
Cash dateSep 30, 2026Source2026-09-30
Runway8.6 monthsSource2026-09-30
Dilution 1y20.3 %Source2026-11-10
Cap5,441,996 USDSource2026-11-13

Sources

Automated from SEC filings and market data. No AI. For information only. Not investment advice.

Discuss in MarginsX More from the Data Desk

More on MarginsX

Companies in this article

Topics

Related Data Desk stories

Every Data Desk article: /desk · RSS